ArticleCardiovascular drugs and therapy2026
Heart Failure with Preserved Ejection Fraction as a Risk Factor for Atrial Fibrillation Recurrence after Ablation.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeAtrial fibrillation (AF) recurrence after radiofrequency ablation is closely associated with patient prognosis, while the potential impact of heart failure with preserved ejection fraction (HFpEF) remains unclear. This study aimed to explore the effect of HFpEF on recurrence within 1 year after catheter ablation.
methodsWe enrolled 455 patients who underwent atrial fibrillation ablation, with 241 in the HFpEF group and 213 in the non-heart failure (non-HF) group. Baseline characteristics, 12-month AF recurrence rates, and predictors were compared between groups. Kaplan-Meier survival analysis and Cox proportional hazards regression model were used to assess the recurrence risk, and propensity score matching (PSM) was performed for verification.
resultsThe HFpEF group exhibited significantly higher recurrence than the non-HF group (25.0% vs. 9.8%, P < 0.001), and Kaplan-Meier analysis confirmed significant differences in 1-year recurrence-free survival (Log-rank P < 0.001). Multivariable Cox regression identified HFpEF as an independent risk factor for 1-year recurrence (HR = 1.92, 95% CI:1.06-3.47), whereas paroxysmal AF was a protective factor(HR = 0.55, 95% CI:0.31-0.98). Subgroup analysis further revealed that compared with the paroxysmal AF without heart failure (NoHF-pAF) group, HFpEF with persistent AF (HFpEF-PerAF) had significantly elevated recurrence risk (adjusted HR = 4.12, 95% CI:2.20-7.75; P < 0.001), and HFpEF with paroxysmal AF (HFpEF-pAF) also showed increased risk (HR = 2.58, 95% CI:1.14-5.84, P = 0.023). After PSM, the HFpEF group maintained significantly higher recurrence (23.0% vs. 10.0%, P = 0.016), with HFpEF remaining the sole independent predictor (HR = 2.42, 95% CI:1.17-5.00, P = 0.017).
conclusionHFpEF is an independent risk factor for 1-year recurrence after AF ablation, with highest risk in persistent AF patients. Implementing comprehensive individualized treatment strategies is essential to improve prognosis.
Indexed as
Identifiers
41636978What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.